Qlaris Bio Appoints Fred Guerard, as President and CEO

Qlaris Bio, Inc., a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s Board of Directors.

“I am honored to join Qlaris at this pivotal moment,” said Dr. Guerard. “QLS-111 represents a differentiated and potentially transformative approach to lowering intraocular pressure by targeting the episcleral vein through its novel vasodilatory mechanism. I look forward to working with Qlaris’ talented team to advance our Phase 3 program and prepare the organization for commercialization.”